Skip to main content

Table 1 Patient and tumor characteristics

From: Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy

Characteristics Overall (n = 123)
Age (years), mean ± SD 54.3 ± 7.6
Sex, n (%)
 Man 117 (95.1)
 Woman 6 (4.9)
ECOG performance status, n (%)
 0 105 (85.4)
 1 18 (14.6)
Pathology, n (%)
 SCC 120 (97.6)
 Adenocarcinoma 3 (2.4)
Location, n (%)
 Upper 24 (19.5)
 Middle 59 (48.0)
 Lower 40 (32.5)
BMI (kg/m2), mean ± SD 22.1 ± 3.3
Histologic grade, n (%)
 Grade 1 12 (9.8)
 Grade 2 88 (71.5)
 Grade 3 23 (18.7)
Smoking, n (%)
 No (never smoked or quitted) 7 (5.7)
 Yes (current smoker) 116 (94.3)
Clinical T stage, n (%)
 cT1 1 (0.8)
 cT2 36 (29.3)
 cT3 80 (65.0)
 cT4a 6 (4.9)
Clinical N stage, n (%)
 cN0 14 (11.4)
 cN1 57 (46.3)
 cN2 39 (31.7)
 cN3 13 (10.6)
cTNM stage, n (%)
 II 31 (25.2)
 III 92 (74.8)
Gross tumor volume (ml), mean ± SD 100.9 ± 73.2
Radiation dose (Gy), median (IQR) 44.0 (43.2–45.0)
 40–44 Gy, n(%) 62 (50.4)
 45–50.4 Gy, n(%) 61 (49.6)
Target volume (ml), mean ± SD 527.6 ± 228.5
Dose-volume of lunga (%), mean ± SD
 V5 74.0 ± 21.2
 V20 20.8 ± 6.4
Mean heart dose (Gy), mean ± SD 18.3 ± 7.6
  1. Abbreviations: BMI body mass index, ECOG Eastern Cooperative Oncology Group, IQR interquartile range, SCC squamous cell carcinoma, SD standard deviation
  2. aVx = volume (mL) of lung receiving X Gy or more